Bloom Burton Forecasts BioSyent’s FY2026 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX) – Equities researchers at Bloom Burton decreased their FY2026 earnings per share estimates for shares of BioSyent in a report released on Tuesday, May 20th. Bloom Burton analyst D. Martin now expects that the company will earn $0.86 per share for the year, down from their previous forecast of $0.88. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.93 EPS.

BioSyent Stock Performance

CVE RX opened at C$11.70 on Wednesday. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91. The stock’s 50 day simple moving average is C$10.80 and its 200-day simple moving average is C$11.06. The company has a market cap of C$133.82 million, a PE ratio of 18.99 and a beta of 0.93. BioSyent has a 1-year low of C$8.88 and a 1-year high of C$12.13.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.